Tag Archives: Lilly

Saving Haiti: One Donation at a Time (UPDATED 1/21)

Image by American Red Cross via Flickr It’s been less than three days since new broke of a massive earthquake in Haiti that all but leveled the struggling country. With thousands dead, a devastated infrastructure, and no emergency plan, countries and businesses around the world have joined in the effort to help the Haitian people with [...]
Posted in News | Also tagged , , , , , , , | 1 Comment

Lilly Osteoporosis Drug Canned in Phase III Trials

Image by go elsewhere… via Flickr Lilly, on Wednesday, announced that it would not seek regulatory approval for its osteoporosis treatment arzoxifene, because the drug failed to meet certain end points in Phase III clinical trials. The good news is that the drug was successful in meeting the primary end point of the trial, dubbed “GENERATIONS.” [...]
Posted in Strategy | Also tagged , , , , , | Leave a comment

Lilly Sales Force Buyouts Revealed

Image via Wikipedia Lilly, on Tuesday, announced that it will offer 4,000 sales reps a buyout in hopes of reducing its sales force by 300 before year’s end. According to a Lilly spokesperson, this is a voluntary exit program for eligible sales force professionals in its diabetes, neuroscience, and osteoporosis business units. Reps have the opportunity [...]
Posted in News | Also tagged , , , | Leave a comment

Pharm Exec Podcast Series:
Bill Trombetta Industry Audit (Part 2)

[display_podcast] Continuing Pharm Exec editor Patrick Clinton’s conversation with Bill Trombetta on the top four pharma companies and what makes them special. Eli Lilly: With double-digit growth in sales, and a solid improvement in revenue per employee, Lilly placed fourth in the Company of the Year rundown. Bill Trombetta explains Lilly’s position as a big/small pharma and [...]
Posted in R&D, Safety, Strategy | Also tagged , , | Leave a comment

Lilly Puts Up $6.5 Billion for ImClone

Lilly broke the news Monday morning that ImClone had accepted its offer to acquire the biotech firm for $6.5 billion or $70 per share—Lilly’s largest acquisition ever. With this purchase Lilly gains control of ImClone’s blockbuster, targeted cancer agent Erbitux, which is marketed for second- and third-line colon cancer and refractory head and neck cancer. ImClone also [...]
Posted in Biotech, Deals | Also tagged , , , , , , , | 1 Comment